The AGO1 Knockout HT29 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from HT29 colorectal adenocarcinoma cells, designed to disrupt the AGO1 gene and ablate its function. This model provides a loss-of-function system for investigating the roles of Argonaute 1 in miRNA-mediated gene silencing and post-transcriptional regulation. The polyclonal format preserves genetic heterogeneity, allowing researchers to observe population-level consequences of AGO1 disruption without single-cell cloning artifacts. Cells are ideal for studying the core RNA-induced silencing complex (RISC) machinery in a human epithelial cancer background.
The parental HT29 cell line originates from a primary colorectal adenocarcinoma and exhibits epithelial morphology, serving as a classic model for intestinal epithelial biology and colorectal cancer research. HT29 cells retain key features of transformed intestinal epithelium, including the ability to polarize and form tight junctions, making them valuable for studying barriers, differentiation, and oncogenic signaling. Their widespread use in cancer biology, drug screening, and signal transduction studies provides a well-characterized context for interrogating gene function. This background enables rigorous comparison with existing literature while exploring AGO1-dependent phenotypes.
AGO1 is a central component of the RISC, directly binding mature miRNAs to guide sequence-specific target mRNA recognition and subsequent translational repression or decay. It functions downstream of the miRNA biogenesis pathway, where primary transcripts are processed by the Drosha-DGCR8 microprocessor, exported by Exportin-5, and cleaved by DICER1 to generate duplex miRNAs. TARBP2 facilitates loading of the guide strand into AGO1-containing complexes. Within RISC, AGO1 interacts with TNRC6A (GW182) to recruit the CCR4-NOT deadenylase complex and repress translation. Knockout of AGO1 disrupts these interactions, impairing silencing of downstream targets such as CDK6, MYC, BCL2, and ZEB1. Consequently, pathways controlling cell cycle progression, apoptosis, and epithelial-mesenchymal transition are dysregulated. Key interacting factors like HSP90, MOV10, and PIWIL1 further modulate AGO1 stability and activity, highlighting its network centrality.
In the colorectal adenocarcinoma context, AGO1??s role in miRNA regulation intersects with tumor suppression and differentiation. miRNAs like let-7, regulated by LIN28A, are known to target oncogenes, and AGO1 mediates their effects. Disruption of AGO1 in HT29 cells permits dissection of miRNA-dependent proliferative and anti-apoptotic signaling, particularly via MYC and BCL2. Furthermore, ZEB1, a master regulator of epithelial-mesenchymal transition, is a direct miRNA target; AGO1 loss may enhance ZEB1 expression, influencing invasive potential. This model thus enables investigation of how RISC components contribute to colorectal cancer progression and response to microenvironmental cues. It serves as a platform for validating miRNA-target interactions and identifying context-specific dependencies.
Typical research applications include miRNA functional studies, where loss of AGO1 uncouples miRNA expression from target repression, enabling identification of genuine miRNA targets via RNA-seq or dual-luciferase reporter assays. The model supports co-immunoprecipitation experiments to map RISC component interactions and assess assembly dynamics. Proliferation and apoptosis assays can reveal AGO1??s impact on cell fate decisions, while miRNA profiling defines altered expression landscapes. Drug target validation studies benefit from this genetic tool to confirm on-target effects of miRNA modulators. Researchers can integrate this knockout with existing HT29-based models of intestinal barrier function or tumor spheroid formation. For technical support or additional information, please contact Ascent Research.
